Mutation News and Research

RSS

New software programs may help speed up drug discovery process for diabetes and other diseases

Proteins sometimes run amuck. All the good stuff (the useful genetic and biological material) they contain can get distorted. Mutations in specific amino acids can cause long strands of proteins to curl in on themselves (like a ball of wool a cat has played with) and refuse to break apart.

30 Sep 2015

Researchers unlock structural details of key protein to treat neuromuscular disease

Researchers at Rice University and Baylor College of Medicine have unlocked the structural details of a protein seen as key to treating a neuromuscular disease.

30 Sep 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

New report implicates five genetic regions that play major roles in CF disease severity

If you have two faulty copies of the CFTR gene, you will have cystic fibrosis. But the severity of your disease will depend on environmental factors and many other genes. Locating these genes and altering their function could lead to new therapies.

29 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.

From EKF Diagnostics 29 Sep 2015

Unique molecule can bind HIV-infected cells to killer T cells

A unique molecule developed at Duke Medicine, the University of North Carolina at Chapel Hill and MacroGenics, Inc., is able to bind HIV-infected cells to the immune system's killer T cells. It could become a key part of a shock-and-kill strategy being developed in the hope of one day clearing HIV infection.

29 Sep 2015

Scientists develop new molecular toolkit to investigate protein assemblies in human disease

A photograph may reveal how something looks, but direct observation can divulge how the objects behave. The difference can mean life or death, especially when it comes to fighting human disease.

29 Sep 2015

New single-molecule tool may help detect interactions between DNA and enzymatic proteins

A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

29 Sep 2015

UT Southwestern Medical Center geneticist named 2015 recipient of Pearl Meister Greengard Prize

UT Southwestern Medical Center geneticist Dr. Helen Hobbs is the 2015 recipient of the prestigious Pearl Meister Greengard Prize. The prize recognizes Dr. Hobbs' research, which advances understanding of heart disease and other complex disorders.

29 Sep 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour tissue as a sample. The test identifies 42 mutations in the epidermal growth factor receptor (EGFR) gene, the most of any In-vitro Diagnostic (IVD) on the market, and can also be used as an aid in selecting eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI).

From Roche Sequencing and Life Science 28 Sep 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

Increasing availability of genetic tests for at-risk cancer patients

Mutations in the BRCA 1 and BRCA 2 genes are very likely to lead to a form of cancer in people who have them. These mutations can be detected using a genetic test. The introduction of a new drug has improved treatment options and this, coupled with increased awareness and improved access, increased the number of genetic tests carried out at the MedUni Vienna last year by a factor of five.

28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Nivolumab drug improves survival for non-SQ NSCLC patients

Patients with a type of lung cancer called non-squamous non-small cell lung cancer (non-SQ NSCLC) have limited treatment options and a dismal prognosis once their disease has advanced and initial treatment with platinum-based chemotherapy has failed. Second-line treatment is usually with another chemotherapy drug, such as docetaxel or pemetrexed.

28 Sep 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene.

28 Sep 2015

Combination of two targeted therapies increases survival in advanced melanoma

Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

28 Sep 2015

Genetic mutations predict breast cancer relapse

A large genetics study has identified genetic mutations specific to recurrent breast cancer cells. Screening for these mutations in breast cancer tumours could therefore allow doctors to identify patients most at risk of their cancer returning. The relevant genes can then be targeted to prevent recurrence of the cancer.

27 Sep 2015

Researchers find mutated gene responsible for cardiac angiosarcoma in two brothers

A few years ago, Javier Benítez, director of the Human Genetics Group at the CNIO, received a call from Pablo García Pavía, from the Cardiology Unit of the Puerta de Hierro University Hospital. This cardiologist was treating two brothers with a rare form of cancer, cardiac angiosarcoma (CAS).

26 Sep 2015

Soft palate study reveals how flu viruses acquire the ability to move between people

National Institutes of Health scientists and their colleagues identified a previously unappreciated role for the soft palate during research to better understand how influenza (flu) viruses acquire the ability to move efficiently between people.

26 Sep 2015

Mutation News and Research

New software programs may help speed up drug discovery process for diabetes and other diseases

Researchers unlock structural details of key protein to treat neuromuscular disease

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

New report implicates five genetic regions that play major roles in CF disease severity

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

Unique molecule can bind HIV-infected cells to killer T cells

Scientists develop new molecular toolkit to investigate protein assemblies in human disease

New single-molecule tool may help detect interactions between DNA and enzymatic proteins

UT Southwestern Medical Center geneticist named 2015 recipient of Pearl Meister Greengard Prize

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Increasing availability of genetic tests for at-risk cancer patients

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Nivolumab drug improves survival for non-SQ NSCLC patients

Two-drug combination improves progression-free survival in patients with advanced melanoma

Combination of two targeted therapies increases survival in advanced melanoma

Genetic mutations predict breast cancer relapse

Researchers find mutated gene responsible for cardiac angiosarcoma in two brothers

Soft palate study reveals how flu viruses acquire the ability to move between people

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News